RB1 and neoplasm: As the Rb pathway is generally compromised in tumor cells, this strategy has the potential of identifying targets for anticancer drugs, because inactivating a gene that is synthetic lethal with loss of Rb activity could preferentially reduce the viability of cancer cells.